Price
Financials
Standalone, Rs crore| Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Operating Profit | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| OPM % | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 |
| Profit before tax | -0.03 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS in Rs | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 7.00 | 9.27 | 16.86 | 8.15 | 2.22 | 0.04 | 0.00 | 0.00 |
| Expenses | 5.76 | 7.54 | 13.63 | 7.76 | 22.22 | 0.57 | 0.12 | 0.02 |
| Operating Profit | 1.24 | 1.73 | 3.23 | 0.39 | -20.00 | -0.53 | -0.12 | -0.02 |
| OPM % | 17.71% | 18.66% | 19.16% | 4.79% | -900.90% | -1,325.00% | ||
| Other Income | 1.01 | 1.56 | 0.10 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest | 0.28 | 0.62 | 1.16 | 1.12 | 0.52 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.16 | 0.21 | 0.22 | 0.23 | 0.12 | 0.07 | 0.07 | 0.11 |
| Profit before tax | 1.81 | 2.46 | 1.95 | -0.96 | -20.64 | -0.60 | -0.18 | -0.13 |
| Tax % | 7.18% | 12.60% | 9.74% | 1.04% | 0.00% | 0.00% | 0.00% | |
| Net Profit | 1.68 | 2.15 | 1.76 | -0.97 | -20.64 | -0.60 | -0.18 | -0.12 |
| EPS in Rs | -1.18 | -25.17 | -0.73 | -0.22 | -0.16 | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | -100% | ||
| Compounded Profit Growth | % | % | 22% | 20% | ||
| Stock Price CAGR | 0% | % | % | % | ||
| Return on Equity | % | -19% | -32% | -1% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4.10 | 4.10 | 4.10 | 8.20 | 8.20 | 8.20 | 8.20 |
| Reserves | 0.94 | 6.76 | 8.52 | 32.01 | 11.13 | 10.54 | 10.36 |
| Borrowings | 5.17 | 10.13 | 14.14 | 16.59 | 16.66 | 16.96 | 17.10 |
| Other Liabilities | 4.33 | 6.40 | 7.84 | 8.88 | 9.60 | 9.53 | 9.43 |
| Total Liabilities | 14.54 | 27.39 | 34.60 | 65.68 | 45.59 | 45.23 | 45.09 |
| Fixed Assets | 2.67 | 7.38 | 7.59 | 7.42 | 35.10 | 34.86 | 34.79 |
| CWIP | 0.00 | 5.92 | 7.34 | 7.62 | 0.00 | 0.00 | 0.00 |
| Investments | 1.30 | 1.30 | 1.30 | 1.30 | 1.30 | 1.30 | 1.31 |
| Other Assets | 10.57 | 12.79 | 18.37 | 49.34 | 9.19 | 9.07 | 8.99 |
| Total Assets | 14.54 | 27.39 | 34.60 | 65.68 | 45.59 | 45.23 | 45.09 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -3.33 | 1.79 | -1.64 | 0.77 | -9.56 | -0.47 | -0.11 |
| Cash from Investing Activity | -0.05 | -5.28 | -1.90 | -0.89 | -19.88 | 0.17 | -0.02 |
| Cash from Financing Activity | 3.38 | 5.99 | 1.21 | 29.97 | -0.45 | 0.36 | 0.13 |
| Net Cash Flow | 0.00 | 2.50 | -2.33 | 29.85 | -29.89 | 0.06 | 0.00 |
| Free Cash Flow | -3.38 | -3.49 | -3.54 | -0.12 | -38.25 | -0.30 | -0.12 |
| CFO/OP | -265% | 103% | -51% | 197% | 48% | 89% | 92% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 159.56 | 120.88 | 163.45 | 320.66 | 44.39 | 2,920.00 | |
| Inventory Days | 187.68 | 198.51 | 113.16 | 252.04 | 6.53 | 0.00 | |
| Days Payable | 477.84 | 353.79 | 277.75 | 706.40 | 827.08 | ||
| Cash Conversion Cycle | -130.60 | -34.41 | -1.14 | -133.69 | -776.16 | 2,920.00 | |
| Working Capital Days | 255.50 | 141.75 | 214.54 | 424.12 | -159.48 | -8,942.50 | |
| ROCE % | 19.81% | 13.24% | 0.41% | -43.37% | -1.67% | -0.50% |
| Jun 2016 | |
|---|---|
| Promoters | 0.60% |
| FIIs | 6.35% |
| DIIs | 4.54% |
| Public | 88.51% |
| No. of Shareholders | 3,957 |
Fundamentals
Market Cap₹ 0.66 Cr.
Current Price₹ 0.81
Book Value₹ 21.8
ROCE-0.50 %
ROE-0.97 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-100%
Compounded Profit Growth (TTM)20%
Standalone figures.
Valuation
P/E, 3-year average17.66x
P/B, 3-year average2.10x
Profitability
Operating margin (excl. other income)4.79%
Operating margin (incl. other income)4.79%
EBITDA margin13.50%
Pre-tax margin-1.60%
Net profit margin-1.47%
ROE-3.67%
ROCE0.38%
ROA-1.93%
ROE, 3-year average12.79%
ROCE, 3-year average11.05%
ROA, 3-year average4.67%
ROIC (approx.)3.74%
Tax rate-1.04%
Growth
Sales growth (latest year)-51.66%
Profit growth (latest year)-155.11%
Sales CAGR, 3 years5.20%
Per share
EPS (TTM)Rs -0.15
EPS (latest year)Rs -1.18
EPS (latest quarter)Rs -0.04
EPS, 3-year averageRs 2.78
Book value per shareRs 49.04
Sales per shareRs 9.94
Cash flow per shareRs 0.94
Free cash flow per shareRs -0.15
Efficiency
Asset turnover0.12x
Fixed asset turnover1.10x
Inventory turnover1.88x
Inventory days194 days
Debtor days321 days
Debtors turnover1.14x
Creditor days827 days
Cash conversion cycle2920 days
Working capital days-8942 days
Leverage
Total debtRs 17 Cr
Cash and bankRs 30 Cr
Net debtRs -13 Cr
Debt to equity0.41x
Net debt / EBITDA-12.22x
Interest coverage0.88x
Owners' fund to total sources61.22%
Debt to assets25.26%
Cash flow
Cash from Operating Activity (latest year)Rs 1 Cr
Cash from Investing Activity (latest year)Rs -1 Cr
Cash from Financing Activity (latest year)Rs 30 Cr
Net Cash Flow (latest year)Rs 30 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs 2 Cr
Sales to cash flow10.58x
Statement figures
Net sales (TTM)Rs 8 Cr
Net sales (latest year)Rs 8 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs -0 Cr
Profit before tax (TTM)Rs -0 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -1 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 6 Cr
Total expenditure (latest year)Rs 8 Cr
Total income (latest year)Rs 8 Cr
Share capitalRs 8 Cr
ReservesRs 32 Cr
Shareholders' fundsRs 40 Cr
Total assetsRs 66 Cr
Net blockRs 7 Cr
Capital work in progressRs 8 Cr
InvestmentsRs 1 Cr
ReceivablesRs 7 Cr
InventoryRs 3 Cr
Other liabilitiesRs 9 Cr
Shares outstanding (crore)0.82
Ownership
Promoter holding0.60%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 4 of 8| explain | Weak cash conversion Cash from operations was 31% of net profit over the last 3 years |
| explain | Receivables outrunning sales Receivables grew -5% vs sales -52% in 2012 |
| look | Inventory outrunning sales Inventory grew 1% vs sales -52% in 2012 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Sep 2016Sales ₹0 Cr.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of ABL Bio-Technologies Ltd?
ABL Bio-Technologies Ltd (526955) has a market capitalisation of Rs 0.66 Cr. at the close.
What were ABL Bio-Technologies Ltd's latest quarterly results?
In the Sep 2016 quarter, ABL Bio-Technologies Ltd sales was Rs 0 Cr with a net loss of Rs 0 Cr.